Jul 27, 2024, 14:57
Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat
Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on X about a recent paper titled “US Food and Drug Administration’s Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma” published in Journal of Clinical Oncology.
Authors: Edward R. Scheffer Cliff, David A. Russler-Germain, C. Joseph Ross Daval and Aaron S. Kesselheim.
“In Journal of Clinical Oncology we review the development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat, and discuss strategies for FDA Oncology to deal with delayed confirmatory clinical trials.
Read here.”
Source: Edward Cliff/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12